Abstract
OBJECTIVE: To evaluate the clinical efficacy of alisartan isoproxil tablets combined with probiotics in elderly hypertensive patients and analyze factors influencing cardiovascular prognosis. METHODS: A retrospective analysis was conducted on 147 hypertensive patients treated at the East New Town Branch of Yinzhou People's Hospital Community from September 2021 to September 2023. Patients were divided into two groups based on treatment regimen: the control group (n=75, treated with alisartan isoproxil tablets) and the observation group (n=72, treated with alisartan isoproxil tablets combined with probiotics). The total effective rate, blood pressure, inflammatory markers, blood lipids, and vascular endothelial function were assessed before treatment, at 3 months, and at 6 months. The incidence of major adverse cardiovascular events (MACE) was compared between the two groups 6 months after treatment. Univariate and multivariate logistic regression analyses were used to identify risk factors for MACE. RESULTS: The total effective rate in the observation group was significantly higher than that in the control group (P < 0.05). Compared to the control group, the observation group showed lower levels of systolic/diastolic blood pressure, inflammatory markers, blood lipids, endothelin-1, and vascular endothelial growth factor, with a higher level of nitric oxide (all P < 0.05). The incidence of MACE was lower in the observation group than in the control group (P < 0.05). Univariate and multivariate logistic regression analyses indicated that age, BMI, SBP, and DBP were risk factors for MACE. CONCLUSION: Alisartan isoproxil combined with probiotics effectively improves blood pressure, inflammatory markers, blood lipids, and vascular endothelial function in elderly hypertensive patients. Age, BMI, SBP, and DBP are identified as risk factors for MACE and should be addressed early with preventive interventions.